BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miles RR, Arnold S, Cairo MS. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. British Journal of Haematology 2012;156:730-43. [DOI: 10.1111/j.1365-2141.2011.09024.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Said JW. Aggressive B-cell lymphomas: how many categories do we need? Mod Pathol 2013;26 Suppl 1:S42-56. [PMID: 23154748 DOI: 10.1038/modpathol.2012.178] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
2 Handoo A, Dadu T. Flow Cytometry in Pediatric Malignancies. Indian Pediatr 2018;55:55-62. [DOI: 10.1007/s13312-018-1229-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Cairo MS. Rituximab in the treatment of childhood mature B-cell lymphoma: "Where do we go from here". Br J Haematol 2019;185:1017-20. [PMID: 31115041 DOI: 10.1111/bjh.15940] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 El-Mallawany NK, Mutai M, Mtete I, Gopal S, Stanley CC, Wasswa P, Mtunda M, Chasela M, Kamiyango W, Villiera J, Fedoriw Y, Montgomery ND, Liomba GN, Kampani C, Krysiak R, Westmoreland KD, Kim MH, Slone JS, Scheurer ME, Allen CE, Mehta PS, Kazembe PN. Beyond Endemic Burkitt Lymphoma: Navigating Challenges of Differentiating Childhood Lymphoma Diagnoses Amid Limitations in Pathology Resources in Lilongwe, Malawi. Glob Pediatr Health 2017;4:2333794X17715831. [PMID: 28680947 DOI: 10.1177/2333794X17715831] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
5 Flepisi BT, Bouic P, Sissolak G, Rosenkranz B. Biomarkers of HIV-associated Cancer. Biomark Cancer 2014;6:11-20. [PMID: 25057241 DOI: 10.4137/BIC.S15056] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
6 de Zwart V, Gouw SC, Meyer-wentrup FA, Meyer-wentrup FA. Antibody therapies for lymphoma in children. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd011181] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Dlamini Z, Mbele M, Makhafola TJ, Hull R, Marima R. HIV-Associated Cancer Biomarkers: A Requirement for Early Diagnosis. Int J Mol Sci 2021;22:8127. [PMID: 34360891 DOI: 10.3390/ijms22158127] [Reference Citation Analysis]
8 Samochatova EV, Maschan AA, Shelikhova LN, Myakova NV, Belogurova MB, Khlebnikova OP, Shamardina AV, Ryskal OV, Roumiantseva JV, Konovalov DM, Dubrovina ME, Rumyantsev AG. Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study. J Pediatr Hematol Oncol 2014;36:395-401. [PMID: 23823112 DOI: 10.1097/MPH.0b013e31829d4900] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
9 Hochberg J, Cairo MS. Lymphoma in Adolescents and Young Adults: Current Perspectives. Cancer J 2018;24:285-300. [PMID: 30480573 DOI: 10.1097/PPO.0000000000000345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Qin C, Huang Y, Feng Y, Li M, Guo N, Rao H. Clinicopathological features and EBV infection status of lymphoma in children and adolescents in South China: a retrospective study of 662 cases. Diagn Pathol 2018;13:17. [PMID: 29482573 DOI: 10.1186/s13000-018-0693-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
11 Zhang Y, Xiang J, Zhu N, Ge H, Sheng X, Deng S, Chen J, Yu L, Zhou Y, Shen J. Curcumin in combination with homoharringtonine suppresses lymphoma cell growth by inhibiting the TGF-β/Smad3 signaling pathway. Aging (Albany NY) 2021;13:18757-68. [PMID: 34324434 DOI: 10.18632/aging.203319] [Reference Citation Analysis]
12 Maschan A, Myakova N, Aleinikova O, Abugova Y, Ponomareva N, Belogurova M, Fechina L, Fedorova A, Grigor'eva N, Lebedev V, Nikonova O, Shamardina A, Sharapova G, Smirnova N, Rudneva A, Volchkov E, Samochatova E. Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M. Br J Haematol 2019;186:477-83. [PMID: 31069789 DOI: 10.1111/bjh.15944] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
13 Forero-castro M, Robledo C, Lumbreras E, Benito R, Hernández-sánchez JM, Hernández-sánchez M, García JL, Corchete-sánchez LA, Tormo M, Barba P, Menárguez J, Ribera J, Grande C, Escoda L, Olivier C, Carrillo E, García de Coca A, Ribera J, Hernández-rivas JM. The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab. Br J Haematol 2016;172:428-38. [DOI: 10.1111/bjh.13849] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
14 Amoils M, Truong MT. Burkitt lymphoma presenting as facial nerve paresis. International Journal of Pediatric Otorhinolaryngology Extra 2016;13:9-12. [DOI: 10.1016/j.pedex.2016.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Liang Y, Ding L, Li X, Wang W, Zhang X. Oculomotor nerve palsy as a preceding symptom of adult sporadic Burkitt lymphoma: A case report and review of the literature. Oncol Lett 2017;13:1315-8. [PMID: 28454254 DOI: 10.3892/ol.2017.5583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
16 Lee S, Day NS, Miles RR, Perkins SL, Lim MS, Ayello J, van de Ven C, Harrison L, El-Mallawany NK, Goldman S, Cairo MS. Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. Br J Haematol 2017;177:601-11. [PMID: 28474336 DOI: 10.1111/bjh.14604] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
17 Miron I, Miron L, Lupu VV, Ignat A. Silent presentation of multiple metastasis Burkitt lymphoma in a child: A case report and review of the literature. Medicine (Baltimore) 2017;96:e7518. [PMID: 28700504 DOI: 10.1097/MD.0000000000007518] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
18 Chu Y, Yahr A, Huang B, Ayello J, Barth M, S Cairo M. Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice. Oncoimmunology 2017;6:e1341031. [PMID: 28932644 DOI: 10.1080/2162402X.2017.1341031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
19 Meyer-Wentrup F, de Zwart V, Bierings M. Antibody therapy of pediatric B-cell lymphoma. Front Oncol 2013;3:68. [PMID: 23565504 DOI: 10.3389/fonc.2013.00068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
20 Atun R, Bhakta N, Denburg A, Frazier AL, Friedrich P, Gupta S, Lam CG, Ward ZJ, Yeh JM, Allemani C, Coleman MP, Di Carlo V, Loucaides E, Fitchett E, Girardi F, Horton SE, Bray F, Steliarova-Foucher E, Sullivan R, Aitken JF, Banavali S, Binagwaho A, Alcasabas P, Antillon F, Arora RS, Barr RD, Bouffet E, Challinor J, Fuentes-Alabi S, Gross T, Hagander L, Hoffman RI, Herrera C, Kutluk T, Marcus KJ, Moreira C, Pritchard-Jones K, Ramirez O, Renner L, Robison LL, Shalkow J, Sung L, Yeoh A, Rodriguez-Galindo C. Sustainable care for children with cancer: a Lancet Oncology Commission. Lancet Oncol 2020;21:e185-224. [PMID: 32240612 DOI: 10.1016/S1470-2045(20)30022-X] [Cited by in Crossref: 41] [Cited by in F6Publishing: 11] [Article Influence: 20.5] [Reference Citation Analysis]
21 Ozuah NW, Lubega J, Allen CE, El-Mallawany NK. Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa. Blood Adv 2020;4:4007-19. [PMID: 32841337 DOI: 10.1182/bloodadvances.2020002178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
22 Lin Y, Pan YH, Li MK, Zong XD, Pan XM, Tan SY, Guo YW. Clinical presentation of gastric Burkitt lymphoma presenting with paraplegia and acute pancreatitis: A case report. World J Gastroenterol 2021; 27(45): 7844-7854 [PMID: 34963746 DOI: 10.3748/wjg.v27.i45.7844] [Reference Citation Analysis]
23 Satwani P, Jin Z, Martin PL, Bhatia M, Garvin JH, George D, Chaudhury S, Talano J, Morris E, Harrison L. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia. 2015;29:448-455. [PMID: 24938649 DOI: 10.1038/leu.2014.194] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
24 Worch J, Rohde M, Burkhardt B. Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives. Pediatr Hematol Oncol 2013;30:465-83. [PMID: 23570584 DOI: 10.3109/08880018.2013.783891] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
25 Vedham V, Verma M, Mahabir S. Early-life exposures to infectious agents and later cancer development. Cancer Med 2015;4:1908-22. [PMID: 26377256 DOI: 10.1002/cam4.538] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
26 Wagener R, Aukema SM, Schlesner M, Haake A, Burkhardt B, Claviez A, Drexler HG, Hummel M, Kreuz M, Loeffler M, Rosolowski M, López C, Möller P, Richter J, Rohde M, Betts MJ, Russell RB, Bernhart SH, Hoffmann S, Rosenstiel P, Schilhabel M, Szczepanowski M, Trümper L, Klapper W, Siebert R; on behalf of the ICGC MMML-Seq-Project and the “Molecular Mechanisms in Malignant Lymphomas” Network Project of the Deutsche Krebshilfe. The PCBP1 gene encoding poly(rc) binding protein i is recurrently mutated in Burkitt lymphoma: PCBP1 MUTATIONS IN BURKITT LYMPHOMA. Genes Chromosomes Cancer 2015;54:555-64. [DOI: 10.1002/gcc.22268] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
27 Auerbach A, Aguilera NS. Epstein-Barr virus (EBV)-associated lymphoid lesions of the head and neck. Semin Diagn Pathol 2015;32:12-22. [PMID: 25804341 DOI: 10.1053/j.semdp.2014.12.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
28 Zeng R, Tang Y, Zhou H, Liu Y, Huang J, Li L, Liu W, Feng Y, Zhou Y, Chen T, Zhang L, Zhong M. STAT3 mediates multidrug resistance of Burkitt lymphoma cells by promoting antioxidant feedback. Biochem Biophys Res Commun 2017;488:182-8. [PMID: 28483518 DOI: 10.1016/j.bbrc.2017.05.031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
29 Hochberg J, Flower A, Brugieres L, Cairo MS. NHL in adolescents and young adults: A unique population. Pediatr Blood Cancer 2018;65:e27073. [PMID: 29741220 DOI: 10.1002/pbc.27073] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
30 Tamayo-Orbegozo E, Amo L, Díez-García J, Amutio E, Riñón M, Alonso M, Arana P, Maruri N, Larrucea S. Emerging Role of Podocalyxin in the Progression of Mature B-Cell Non-Hodgkin Lymphoma. Cancers (Basel) 2020;12:E396. [PMID: 32046309 DOI: 10.3390/cancers12020396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Aukema SM, Theil L, Rohde M, Bauer B, Bradtke J, Burkhardt B, Bonn BR, Claviez A, Gattenlöhner S, Makarova O, Nagel I, Oschlies I, Pott C, Szczepanowski M, Traulsen A, Kluin PM, Klapper W, Siebert R, Murga Penas EM. Sequential karyotyping in Burkitt lymphoma reveals a linear clonal evolution with increase in karyotype complexity and a high frequency of recurrent secondary aberrations. Br J Haematol 2015;170:814-25. [DOI: 10.1111/bjh.13501] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
32 Ejaz K, Khan QA, Raza MA, Ahmed RS, Aleem A. High-grade Burkitt Lymphoma Presenting as a Buttock Mass and Foot Drop. Cureus 2018;10:e3368. [PMID: 30510878 DOI: 10.7759/cureus.3368] [Reference Citation Analysis]
33 de Zwart V, Gouw SC, Meyer-Wentrup FA. Antibody therapies for lymphoma in children. Cochrane Database Syst Rev 2016;:CD011181. [PMID: 26784573 DOI: 10.1002/14651858.CD011181.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Ma X, Xu G, Li Z, Chen F, Wu D, Miao J, Zhan Y, Fan Y. HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt’s Lymphoma Cells by Impeding the Cell Cycle. CURR MED SCI 2019;39:228-36. [DOI: 10.1007/s11596-019-2024-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Patel A, Sharma MC, Bakhshi S. Outcome of Early Stage Pediatric Non-Lymphoblastic Non-Hodgkin Lymphoma. Indian J Pediatr 2018;85:782-4. [DOI: 10.1007/s12098-017-2585-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Nobili L, Ronchetti D, Taiana E, Neri A. Long non-coding RNAs in B-cell malignancies: a comprehensive overview. Oncotarget 2017;8:60605-23. [PMID: 28947998 DOI: 10.18632/oncotarget.17303] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
37 López C, Kleinheinz K, Aukema SM, Rohde M, Bernhart SH, Hübschmann D, Wagener R, Toprak UH, Raimondi F, Kreuz M, Waszak SM, Huang Z, Sieverling L, Paramasivam N, Seufert J, Sungalee S, Russell RB, Bausinger J, Kretzmer H, Ammerpohl O, Bergmann AK, Binder H, Borkhardt A, Brors B, Claviez A, Doose G, Feuerbach L, Haake A, Hansmann ML, Hoell J, Hummel M, Korbel JO, Lawerenz C, Lenze D, Radlwimmer B, Richter J, Rosenstiel P, Rosenwald A, Schilhabel MB, Stein H, Stilgenbauer S, Stadler PF, Szczepanowski M, Weniger MA, Zapatka M, Eils R, Lichter P, Loeffler M, Möller P, Trümper L, Klapper W, Hoffmann S, Küppers R, Burkhardt B, Schlesner M, Siebert R; ICGC MMML-Seq Consortium. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nat Commun 2019;10:1459. [PMID: 30926794 DOI: 10.1038/s41467-019-08578-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
38 Hochberg J, El-Mallawany NK, Abla O. Adolescent and young adult non-Hodgkin lymphoma. Br J Haematol. 2016;173:637-650. [PMID: 27071675 DOI: 10.1111/bjh.14074] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
39 Tang Y, Jiao X, Chang X, Huang D. Risk factors for the evaluation of potential central nervous system metastasis in Burkitt's lymphoma: a case study and literature review: Risk factors of CNS metastasis in BL. Hematol Oncol 2016;34:36-41. [DOI: 10.1002/hon.2159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Galardy PJ, Hochberg J, Perkins SL, Harrison L, Goldman S, Cairo MS. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report. Br J Haematol 2013;163:365-72. [PMID: 24032600 DOI: 10.1111/bjh.12542] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
41 Bouattour N, Kamoun F, Charfi S, Nsir SB, Bouchaala W, Boudawara T, Triki C. Neurological Nuance: Sporadic Burkitt's Lymphoma Presenting with Guillain–Barre Syndrome. Journal of Pediatric Neurology 2021;19:054-8. [DOI: 10.1055/s-0040-1710515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Azevedo MM, Pina-Vaz C, Baltazar F. Microbes and Cancer: Friends or Faux? Int J Mol Sci 2020;21:E3115. [PMID: 32354115 DOI: 10.3390/ijms21093115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
43 Chu Y, Lee S, Shah T, Yin C, Barth M, Miles RR, Ayello J, Morris E, Harrison L, Van de Ven C, Galardy P, Goldman SC, Lim MS, Hermiston M, McAllister-Lucas LM, Giulino-Roth L, Perkins SL, Cairo MS. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. Oncoimmunology 2019;8:e1512455. [PMID: 30546948 DOI: 10.1080/2162402X.2018.1512455] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
44 Zhen Z, Zhu J, Wang J, Lu S, Sun F, Huang J, Sun X. Rituximab is highly effective in children and adolescents with Burkitt lymphoma in Risk Groups R2 to R4. Pediatric Hematology and Oncology 2020;37:489-99. [DOI: 10.1080/08880018.2020.1759741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
45 Mărginean CO, Meliţ LE, Horvath E, Gozar H, Chinceşan MI. Non-Hodgkin lymphoma, diagnostic, and prognostic particularities in children - a series of case reports and a review of the literature (CARE compliant). Medicine (Baltimore) 2018;97:e9802. [PMID: 29465563 DOI: 10.1097/MD.0000000000009802] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
46 Davidson A, Hendricks M. Experience with B-cell lymphoma at a South African centre in the HIV Era. Transfusion and Apheresis Science 2013;49:31-9. [DOI: 10.1016/j.transci.2013.05.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
47 Crespo-Solis E, Espinosa-Bautista K, Alvarado-Ibarra M, Rozen-Fuller E, Pérez-Rocha F, Nava-Gómez C, Ortiz-Zepeda M, Álvarez-Vera JL, Ramos-Peñafiel CO, Meillón-García LA, Rodríguez-Rodríguez S, Pomerantz-Okon A, Turrubiates-Hernández FJ, Demichelis-Gómez R. Survival analysis of adult patients with ALL in Mexico City: first report from the Acute Leukemia Workgroup (ALWG) (GTLA). Cancer Med 2018;7:2423-33. [PMID: 29733512 DOI: 10.1002/cam4.1513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, Gonsalves W, Warsame R, Kourelis TV, Chakraborty R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Dingli D, Leung N, Rajkumar SV, Kyle RA, Kumar SK, Gertz MA. Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. Br J Haematol 2017;178:888-95. [PMID: 28699650 DOI: 10.1111/bjh.14830] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
49 Smets F, Sokal EM. Prevention and Treatment for Epstein–Barr Virus Infection and Related Cancers. In: Chang MH, Jeang K, editors. Viruses and Human Cancer. Berlin: Springer Berlin Heidelberg; 2014. pp. 173-90. [DOI: 10.1007/978-3-642-38965-8_10] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
50 Feng K, Wang C, Zhou H, Yang J, Dong L, Zhou K, Liu X, Song Y. [Effect of ERK1/2 inhibitor AZD8330 on human Burkitt's lymphoma cell line Raji cells and its mechanism]. Zhonghua Xue Ye Xue Za Zhi 2015;36:148-52. [PMID: 25778893 DOI: 10.3760/cma.j.issn.0253-2727.2015.02.014] [Reference Citation Analysis]